(Q55473853)

12 July 2018

title

CDKN2A/p16 in ependymomas. (English)

1 reference

12 July 2018

author

Paola Cavalla

3

1 reference

12 July 2018

Alessandro Mauro

5

1 reference

12 July 2018

author name string

S Bortolotto

1

1 reference

12 July 2018

L Chiadò-Piat

2

1 reference

12 July 2018

I Bosone

4

1 reference

12 July 2018

D Schiffer

6

1 reference

12 July 2018

publication date

1 August 2001

1 reference

12 July 2018

Journal of Neuro-Oncology

published in

1 reference

12 July 2018

volume

54

1 reference

12 July 2018

issue

1

1 reference

12 July 2018

page(s)

9-13

1 reference

12 July 2018

https://scigraph.springernature.com/pub.10.1023/a:1012537105775

exact match

0 references

cites work

Ependymoma: a follow-up study of 101 cases

1 reference

12 December 2020

Silencing of p16/CDKN2 expression in human gliomas by methylation and chromatin condensation.

1 reference

12 December 2020

Ependymoma: internal correlations among pathological signs: the anaplastic variant

1 reference

12 December 2020

Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands

1 reference

12 December 2020

CDKN2 (p16/MTS1) gene deletion or CDK4 amplification occurs in the majority of glioblastomas.

1 reference

12 December 2020

Homozygous deletions of the multiple tumor suppressor gene 1 in the progression of human astrocytomas.

1 reference

12 December 2020

p16INK4a and p19INK4d mRNA expression in neuroglial tumours: correlation with Ki67 proliferation index

1 reference

12 December 2020

Infrequency of p53 gene mutations in ependymomas

1 reference

12 December 2020

Lack of histopathological correlation of malignant ependymomas with postoperative survival

1 reference

12 December 2020

CDKN2/p16 predicts survival in oligodendrogliomas: comparison with astrocytomas.

1 reference

12 December 2020

Mutations of the p53 tumor suppressor gene in neoplasms of the human nervous system.

1 reference

12 December 2020

CDKN2/p16 inactivation and p16 immunohistochemistry in astrocytic gliomas.

1 reference

12 December 2020

Infrequent alterations of the p15, p16, CDK4 and cyclin D1 genes in non-astrocytic human brain tumors.

1 reference

12 December 2020

Cell-cycle inhibitor p27/Kip-1 expression in non-astrocytic and non-oligodendrocytic human nervous system tumors.

1 reference

12 December 2020

CDKN2/p16 or RB alterations occur in the majority of glioblastomas and are inversely correlated.

1 reference

12 December 2020

Molecular genetic correlates of p16, cdk4, and pRb immunohistochemistry in glioblastomas.

1 reference

12 December 2020

5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers

1 reference

12 December 2020

Hypermethylation of the CpG island of p16/CDKN2 correlates with gene inactivation in gliomas.

1 reference

12 December 2020

Clinicopathologic study of 61 patients with ependymoma including MIB-1 immunohistochemistry.

1 reference

12 December 2020

CDKN2A/p16 inactivation in the prognosis of oligodendrogliomas.

1 reference

12 December 2020

Anaplastic ependymomas: clinical features and tumour suppressor gene p53 analysis.

1 reference

12 December 2020

Mutation rate of the CDKN2 gene in malignant gliomas.

1 reference

12 December 2020

MTS1/p16/CDKN2 lesions in primary glioblastoma multiforme.

1 reference

12 December 2020

Infrequent methylation of CDKN2A(MTS1/p16) and rare mutation of both CDKN2A and CDKN2B(MTS2/p15) in primary astrocytic tumours

1 reference

12 December 2020

Identifiers

DOI

10.1023/A:1012537105775

1 reference

12 July 2018

Dimensions Publication ID

0 references

1 reference

12 July 2018